ميرتازاپين تيڤع ۳٠ ملغ Իսրայել - արաբերեն - Ministry of Health

ميرتازاپين تيڤع ۳٠ ملغ

teva pharmaceutical indust.ltd - mirtazapine 30 mg - tablets - mirtazapine - episode of major depression.

تريتايس ٢٫٥ ملغ Իսրայել - արաբերեն - Ministry of Health

تريتايس ٢٫٥ ملغ

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

لوثيماكس Իսրայել - արաբերեն - Ministry of Health

لوثيماكس

salomon,levin & elstein ltd - loteprednol etabonate 5 mg / 1 ml - ophthalmic suspension - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

پريمولوت-نور Իսրայել - արաբերեն - Ministry of Health

پريمولوت-نور

bayer israel ltd - norethisterone acetate 5 mg - tablets - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.